바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.69 No.2
Citation Share

A Case of Ischemic Colitis Associated with Paclitaxel Loaded Polymeric Micelle (Genexol-PMⓇ) Chemotherapy

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2010, v.69 no.2, pp.115-118

Hyun-Wook Kang
Tae-Ok Kim
Ho-Seok Ki
Eun-Young Kim
Hee-Jung Ban
Byeong-Kab Yoon







Hyun-Wook, K. , Tae-Ok, K. , Ho-Seok, K. , Eun-Young, K. , Hee-Jung, B. , Byeong-Kab, Y. , & (2010). A Case of Ischemic Colitis Associated with Paclitaxel Loaded Polymeric Micelle (Genexol-PMⓇ) Chemotherapy. Tuberculosis & Respiratory Diseases, 69(2), 115-118.
  • Downloaded
  • Viewed
PDF Download

Abstract

Paclitaxel has been widely used for treating many solid tumors. Although colonic toxicity is an unusual complication of paclitaxel-based chemotherapy, the reported toxicities include pseudomembranous colitis, neutropenic enterocolitis and on rare occasions ischemic colitis. Genexol-PMⓇ, which is a recently developed cremophor-free, polymeric micelle-formulated paclitaxel, has shown a more potent antitumor effect because it can increase the usual dose of paclitaxel due to that Genexol-PMⓇ does not include the toxic cremophor compound. We report here on a case of a 57-year-old man with advanced non-small cell lung cancer and who developed ischemic colitis after chemotherapy with Genexol-PMⓇ and cisplatin. He complained of hematochezia with abdominal pain on the left lower quadrant. Colonoscopy revealed diffuse mucosal hemorrhage and edema from the sigmoid colon to the splenic flexure. After bowel rest, he recovered from his symptoms and the follow-up colonoscopic findings showed that the mucosa was healing. Since then, he was treated with pemetrexed monotherapy instead of a paclitaxel compound and platinum.

keywords
Paclitaxel, Genexol-PM, Colitis, Ischemic

Reference

1.

1. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C,Murphy B, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1996;14:2054-60.

2.

2. Tashiro M, Yoshikawa I, Kume K, Otsuki M. Ischemic colitis associated with paclitaxel and carboplatin chemotherapy. Am J Gastroenterol 2003;98:231-2.

3.

3. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.Clin Cancer Res 2004;10:3708-16.

4.

4. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:2009-14.

5.

5. Gelderblom H, Verweij J, Nooter K, Sparreboom A.Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8.

6.

6. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72:191-202.

7.

7. Sreenarasimhaiah J. Diagnosis and management of ischemic colitis. Curr Gastroenterol Rep 2005;7:421-6.

8.

8. Seewaldt VL, Cain JM, Goff BA, Tamimi H, Greer B,Figge D. A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. Gynecol Oncol 1997;67:137-40.

9.

9. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat.J Clin Invest 1995;95:1869-76.

10.

10. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ.Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.Cancer Res 1997;57:81-6.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy